AAP
CCCC icon

Arax Advisory Partners’s C4 Therapeutics CCCC Stock Holding History

Arax Advisory Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$839 Buy
319
+300
+1,579% +$706 ﹤0.01% 3332
2025
Q4 		$36 Sell
19
-36
-65% -$85 ﹤0.01% 3974
2025
Q3 		$122 Buy
+55
New +$132 ﹤0.01% 3484

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arax Advisory Partners's CCCC Position: Q1 2026 in Review

Arax Advisory Partners increased its C4 Therapeutics (CCCC) stake by 1,579% in Q1 2026, buying an estimated $706 and bringing the position to 319 shares worth $839. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Arax Advisory Partners first reported a position in CCCC in Q3 2025 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Arax Advisory Partners held 319 shares of C4 Therapeutics worth $839 as of Q1 2026.
  • Arax Advisory Partners bought 300 C4 Therapeutics shares in Q1 2026, an estimated $706.
  • C4 Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3332 holding.
  • Arax Advisory Partners first reported a position in C4 Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.